四川宏明博思藥業(yè)有限公司成立于2013年，專(zhuān)注于原料藥和制劑的生產(chǎn)?，F有員工400余人，主要生產(chǎn)高端劑型如注射劑、凍干粉針劑、片劑和膠囊劑。宏明博思的凍干粉針制劑生產(chǎn)線(xiàn)已獲得EU GMP，并通過(guò)巴西ANVISA現場(chǎng)檢查。目前四川宏明博思凍干粉針制劑的多個(gè)產(chǎn)品在巴西、智利、秘魯、危地馬拉、泰國、菲律賓、馬來(lái)西亞、南非、澳大利亞等開(kāi)展注冊中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
2013年1月，成都百裕金閣萊藥業(yè)有限公司成立
Jan. 2013, Established Chengdu Baiyu Ginkgolide Pharmaceutical Co., Ltd
2013年12月，開(kāi)工奠基
Dec. 2013, Groundbreaking
2018年3月，啟動(dòng)商業(yè)化生產(chǎn)
Mar. 2018, Launched commercial production
2018年4月，與ELC醫藥簽署歐盟2個(gè)產(chǎn)品商務(wù)合同
Apr. 2018, Signed commercial contract with ELC Pharmaceutical for2 products in EU
2022年3月，通過(guò)歐盟認證現場(chǎng)檢查
Mar. 2022, Passed the EU GMP certification on-site inspection
2022年8月，百裕金閣萊更名為四川宏明博思藥業(yè)有限公司
Aug. 2022, Baiyu Ginkgolide changed its name to Sichuan Omnis Pharmaceutical Co. Ltd
2022年12月，四川生物醫藥集團與百裕制藥簽訂戰略協(xié)議
Dec. 2022, Biomedical Industrial Group signed a strategic agreement with Baiyu Pharmaceuticals
2023年1月-2月，取得宏明博思藥品生產(chǎn)許可證產(chǎn)品批件、GMP認證
Jan.-Feb. 2023, Obtained the DML, product certificate, China GMP
2023年5月，取得歐盟認證證書(shū)通過(guò)巴西認證現場(chǎng)審計檢查
May 2023, Granted the EU GMP and passed the on-site audit inspection by ANVISA
2023年7月，取得ANVISA GMP
Jul. 2023, Granted the ANVISA GMP
